BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up on Analyst Upgrade

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) shares gapped up prior to trading on Thursday after Zacks Research upgraded the stock to a hold rating. The stock had previously closed at $19.38, but opened at $20.31. BlossomHill Therapeutics shares last traded at $20.05, with a volume of 15,940 shares changing hands.

A number of other research analysts have also recently issued reports on the company. Guggenheim initiated coverage on BlossomHill Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $30.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They set an “overweight” rating and a $28.00 price target on the stock. Wall Street Zen raised shares of BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Lifesci Capital initiated coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $32.00 target price on the stock. Finally, Leerink Partners assumed coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They set an “outperform” rating and a $36.00 price target for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $32.20.

Insiders Place Their Bets

In related news, Director Bihua Chen purchased 312,500 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the transaction, the director owned 3,614,034 shares of the company’s stock, valued at approximately $57,824,544. This represents a 9.47% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Carl L. Gordon purchased 625,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was bought at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the purchase, the director owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This trade represents a 29.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 1,573,900 shares of company stock valued at $25,181,900 over the last ninety days.

Trending Headlines about BlossomHill Therapeutics

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: HC Wainwright maintains a bullish outlook: The firm initiated research coverage and assigned a “Buy” rating with a $35 price target, implying meaningful upside from recent trading levels. Its estimates also project narrowing losses, from $3.71 per share in fiscal 2026 to $2.99 in fiscal 2027. HC Wainwright coverage
• Positive Sentiment: Broader institutional attention: Guggenheim, Leerink Partners, JPMorgan Chase and Lifesci Capital have also initiated or announced research coverage on BLSM. Expanded analyst coverage can improve investor awareness and potentially increase trading liquidity. Guggenheim coverage
• Positive Sentiment: Upcoming investor presentations: BlossomHill plans to present at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference, giving investors an opportunity to receive updates on its oncology pipeline and development strategy. BlossomHill investor presentations
• Neutral Sentiment: Zacks upgraded BLSM to “Hold.” The change indicates a more neutral stance rather than a strong sell signal, but it may temper the optimism created by the new “Buy” coverage. Zacks rating change
• Negative Sentiment: BlossomHill remains loss-making. HC Wainwright forecasts additional quarterly losses through 2027, including an estimated $3.71-per-share loss for fiscal 2026. The stock therefore remains dependent on clinical progress, future financing and eventual commercialization prospects.

BlossomHill Therapeutics Stock Performance

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.